S. Williams

发表

Biomarkers and Surrogate End Points for Fit‐for‐Purpose Development and Regulatory Evaluation of New Drugs

J. Wagner, S A Williams, J A Wagner, 2007, Clinical pharmacology and therapeutics.

Application of a 27-protein candidate cardiovascular surrogate endpoint to track risk ascendancy and resolution in COVID-19.

N. Hacohen, A. Magis, J. Heath, 2021, medRxiv.

The Value, Qualification, and Regulatory Use of Surrogate End Points in Drug Development

Stephen A. Williams, J. Wagner, C. Girman, 2009, Clinical pharmacology and therapeutics.

A Prototypical Process for Creating Evidentiary Standards for Biomarkers and Diagnostics

D Amakye, S Madani, P. Sager, 2008, Clinical pharmacology and therapeutics.

Proof of Concept: A PhRMA Position Paper With Recommendations for Best Practice

S Madani, S. Cohen, J. Fleishaker, 2010, Clinical pharmacology and therapeutics.